" /> Mobocertinib Succinate - CISMeF





Preferred Label : Mobocertinib Succinate;

NCIt synonyms : TAK-788 Succinate; AP32788 Succinate; TAK788 Succinate; Propan-2-yl 2-[5- (acryloylamino)-4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxyanilino]-4-(1-methyl-1H-indol-3- yl)pyrimidine-5-carboxylate Succinate; AP 32788 Succinate; TAK 788 Succinate; AP-32788 Succinate;

NCIt definition : The succinate salt form of mobocertinib, an orally available inhibitor of human epidermal growth factor receptor (EGFR) exon 20 insertion mutations, with antineoplastic activity. Upon oral administration, mobocertinib, and its active metabolites, specifically and irreversibly binds to and inhibits exon 20 insertion mutations of EGFR. This prevents EGFR-mediated signaling and leads to cell death in tumor cells expressing exon 20 insertion mutations. In addition, mobocertinib may inhibit the activity of other EGFR family members, such as human epidermal growth factor receptor 2 (HER2; ERBB2) and HER4. EGFR, HER-2 and -4 are receptor tyrosine kinases often mutated in numerous tumor cell types. They play key roles in tumor cell proliferation and tumor vascularization.;

UNII : 53QIA92ZEE;

CAS number : 2389149-74-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2389149-74-8 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Exkivity;

NCI Metathesaurus CUI : CL1664838;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
09/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.